In congenital heart disease (CHD), the presence of pulmonary arterial hypertension (PAH) is associated with a poor prognosis. In this study, we aim to investigate the role of pulmonary artery compliance (Cp) in predicting the mortality of PAH associated with adult congenital heart disease (APAH-CHD). One-hundred and seventy-five patients of APAH-CHD who underwent a comprehensive clinical evaluation were included in this study. All patients were followed up in a 6-month interval and the primary end point was all cause of death. The duration of mean follow-up was 67 26 months, of which there were twenty-three death. Cp had an inverse correlation with pulmonary artery resistance (PVR), regardless of the clinical phenotype (Eisenmenger syndrome, PAH with small defect and PAH after defect correction). Patients in the lowest Cp group (Cp ! 0.84 mL/mmHg) had advanced WHO function class, worse exercise tolerance, liver function, and status of oxygen saturation. In univariate cox regression analysis, Cp (HR = 1.359, P < 0.001), PVR (HR = 0.972, P = 0.001), pulmonary blood flow (HR = 1.092, P = 0.001), heart rate (HR = 1.038, P = 0.028) and 6-minute walking distance (HR = 1.003, P = 0.037) were predictors of survival. After adjustment by bivariate analysis, Cp was the independent predictor. Kaplan-Meier survival curves showed that patients with Cp < 1.04 mL/mmHg had worse prognosis. In conclusion, Cp possibly reflects disease severity and decreased Cp was associated with poor prognosis in patients with APAH-CHD.
P ulmonary arterial hypertension (PAH) is a life threatening condition that is characterized by progressive pulmonary arterial remodeling, resulting in elevated pulmonary vascular resistance (PVR) and increased pulmonary artery pressure, that subsequently leads to right heart failure and deaths. 1) Congenital heart disease (CHD) is a common reason of PAH in adults, and about 5-10% patients with congenital heart disease will develop PAH.
2) CHD-related PAH is not rare and is associated with more than doubling of mortality compared with patients without PAH.
3) As had been described, most PAHpatients died from right ventricular failure. Pulmonary vascular compliance (Cp), which quantifies elastic properties of the pulmonary arterial system, is inversely proportional to the workload on the right heart. 4) Previous study showed that Cp is a strong independent predictor of mortality in patients with idiopathic PAH (IPAH). 5) The inverse relationship between Cp and PVR in both normal and diseased pulmonary circulation including IPAH, 6) chronic thromboembolic pulmonary hypertension, 7) and left heart dysfunction 8) had also been established. However, the prognostic relevance of Cp in PAH associated with adult CHD (APAH-CHD) has not been well described. Therefore, in this study we analyzed the prognostic value of Cp in the population of APAH-CHD. In addition, we also investigate the relationship between Cp and PVR in the subtypes of these patients.
Methods
Study population: This study included consecutive patients with APAH-CHD who underwent a comprehensive clinical evaluation in the pulmonary vascular disease center of Fuwai hospital (Beijing, China) between July 2007 and December 2012. Adulthood was defined as age "14 years. PAH was diagnosed by right heart catheterization (RHC) based on the following hemodynamic criteria: mean pulmonary arterial pressure (mPAP) "25 mmHg, Cheng, ET AL pulmonary capillary wedge pressure (PCWP) !15 mmHg and PVR > 3 wood units. We included patients with PAH due to an intracardiac or extracardiac communication. Patients who had PAH after defect correction were also included in this study. All of patients with APAH-CHD were classified into 4 subgroups according to the guidelines.
1) The criteria of diagnosis were elucidated as following: Subgroup 1. Eisenmenger physiology was established by echocardiography as an atrial septal defect with "2 cm effective diameter and/or ventricular septal defect with "1 cm effective diameter associated with reversal or bidirectional shunt; Subgroup 2. PAH associated with systemic-to-pulmonary shunts: Patients had mildly to moderately increased PVR and it was established in the presence of left to right shunt evidenced by echocardiography; Subgroup 3. PAH with small septal defects defined as atrial septal defect < 2 cm effective diameter and ventricular septal defect < 1 cm effective diameter established by echocardiography; Subgroup 4. PAH after defect correction: CHD is repaired, but PAH either persists immediately after correction or recurs months or years in the absence of significant postoperative lesions.
Patients of subgroup 2 were not included in this study because there was a significant left-to-right shunt. Patients who combined with chronic pulmonary diseases, sleep disorders, coronary artery disease, and persistent arrhythmia were excluded. Because pulse pressure is possibly influenced by severe pulmonary regurgitation, patients with significant pulmonary regurgitation were also excluded. All patients'clinical data were collected prospectively. This study complied with the Declaration of Helsinki and was approved by the Institutional Review Board of Fuwai Hospital and informed consents were obtained from all enrolled patients. Laboratory test and echocardiographic evaluation: All subjects underwent comprehensive clinical evaluation, including medical history, physical examination, 12-lead electrocardiogram, chest radiograph and blood test. Routine biochemistry, hematology, and arterial blood gas test were performed when patients referred to the hospital. RHC and transthoracic echocardiography were performed within one week of the blood test. The left ventricular and right ventricular size were measured through a standard view by an experienced sonographer, who was blind of the clinical information. Pulmonary regurgitation was assessed by echo-Doppler as American Society of Echocardiography (ASE) recommendations. 9) If necessary, a CT pulmonary angiography was used to confirm the diagnosis. Hemodynamic parameters: Right heart catheterization was performed in the catheterization laboratory by an experienced cardiologist. Patients were in the supine position, and the system was zeroed and referenced at the level of the heart. A 6F pigtail catheterization was inserted through internal jugular vein. The following hemodynamic parameters were measured: right atrial pressure (RAP), pulmonary artery systolic pressure (Pa sys), pulmonary artery diastolic pressure (Pa dias), and oxygen saturation of different parts of the circulation. In patients who had mPAP "25 mmHg, a Swan-Ganz catheterization was used to get PAWP. Right cardiac output (CO), systemic blood flow (Qs) and pulmonary blood flow (Qp) were determined by Fick's method. PVR was calculated as: (mPAP-PAWP)/CO; Cp was calculated as stroke volume in milliliters divided by pulse pressure (Pa sys-Pa dias). End point and follow up: PAH-targeted therapy including endothelin receptor antagonists, phosphodiesterase type-5 inhibitors, prostanoids, and calcium channel blockers were prescribed as soon as their diagnoses were confirmed by RHC. Drugs were chosen based on the patients' conditions.
All patients were followed up by outpatient clinic interview or telephone contact in a six-month interval from the date of diagnoses. The primary end point was all causes of mortality. Survival data was collected. Statistical analysis: All of the analyses were performed PULMONARY HYPERTENSION, RESISTANCE, MORTALITY Chi-square statistics were used to assess the differences between proportions. The prognostic value of Cp was tested by univariate and bivariate cox proportional hazard regression analysis. The optimal cut-off value of Cp to predict mortality was determined by receiver operating characteristic (ROC) curve analysis. Sensitivity and specificity were also calculated for the cut-off points. Kaplan-Meier curves were used to illustrate the timing of endpoints during follow-up. A P value of ! 0.05 was considered statistically significant.
Results
Baseline demographic, clinical and hemodynamic characteristics: Out of 220 patients with CHD, 175 were included in this study. Eight patients with PVR < 3 wood units were not eligible for this study. Seven patients with a significant left-to-right shunt, twenty-two patients with severe comorbidity, and two patients with moderate or greater pulmonary regurgitation were excluded. Six patients were not analyzed due to missing clinical data. All patients had completed the right heart catheterization successfully with no adverse event.
Demographic and clinical characteristics of the study population are summarized in Table I . We also compared clinical characteristics of patients in three subgroups, and the results are showed in Table II . There was no significant difference in exercise ability, the diameter of left/ right ventricle, level of serum creatinine, and total biliru- bin among the three groups. Patients with Eisenmenger syndrome showed more decreased arterial oxygen pressure (P = 0.001), more increased in hemoglobin (P < 0.001) and higher mPAP (P = 0.015). In the PAH after defect correction group (subgroup 4), patients were much more likely to have higher plasma level of NT-proBNP and bigEndothelin (P < 0.001, P = 0.001, respectively). Despite this, there was a trend of lower Cp in patients with defect correction, the difference was not significant statistically (P = 0.422). Figure 1A displays the scatter plot of PVR and Cp from the overall study population. There was a significant inverse correlation between PVR and Cp (r 2 = 0.65). This relationship was also established in each subgroup. Cp-PVR dependence was not changed by the clinical phenotypes ( Figure 1B, 1C  and 1D ). Clinical and hemodynamic characteristics based on Cp: All of the patients were divided into three tertiles based on the Cp value. Characteristics of patients in the three groups are shown in Table III . There was a significant gradient in severity of most variables among the three groups. Patients in the lower Cp group experienced advanced WHO function class (P = 0.011), worse exercise tolerance (P = 0.009), left ventricular dilation (P = 0.001), liver function (total bilirubin, P = 0.043), and the status of arterial oxygenation (PaO2, P = 0.001). The plasma level of NT-proBNP of the lowest Cp (Cp ! 0.84 mL/mmHg) group was higher (1330.8 ± 925.3 versus 938.9 ± 803.0, 820.0 ± 468.0 pg/mL, P = 0.006) than the others, which means worse right ventricular function in this group.
Relationships between Cp and PVR:
There were advanced hemodynamic profiles in the lowest Cp group, including higher mean right atrial pressure (mRAP, P < 0.001), mPAP (P < 0.001), PVR (P < 0.001) and lower mixed venous oxygen saturation (SVO2, P < 0.001). Figure 2 shows the all-cause mortality of patients in the three Cp tertiles. In the lowest, second, and highest Cp group, the mean follow-up time was 65 ± 22, 72 ± 23 and 63 ± 32 months (P = 0.159), and the mortality was 22.4%, 15.0% and 1.8%, respectively.
Prognostic role of Cp in patients with APAH-CHD:
The duration of the mean follow-up period was 67 ± 26 months, twenty-eight patients(16%) were lost, and 93% patients were followed up for at least three years or until death. There were twenty-three deaths; nineteen were dead due to right heart failure, one was died of pregnancyinduced hypertension, and three were sudden death.
At univariate cox regression analysis, age, sex, targettherapy, WHO function class, 6-minute walking distance (6-MWD), heart rate, hemoglobin, total bilirubin, NTproBNP, PaO2, SVO2, mRAP, Cp, Qp, Qs, pulse pressure, and PVR were the candidate predictors for evaluating survival. The results found that only 6-minute walking distance (HR = 1.003, 95%CI: 1.000-1.005, P = 0.037), heart rate (HR = 1.038, 95%CI:1.004-1.074, P = 0.028), Qp (HR = 1.092, 95%CI: 1.037-1.148, P = 0.001), PVR (HR = 0.972, 95%CI: 0.955-0.989, P = 0.001) and Cp (HR = 1.359, 95% CI: 1.148-1.610, P < 0.001) were associated with survival (Table IV) . Successive bivariate analysis was used to test the independent association between Cp and other variables for predicting survival and the re-PULMONARY HYPERTENSION, RESISTANCE, MORTALITY Hemoglobin*: Patients of Cp ≤ 0.84 mL/mmHg compared with Cp ≥ 1.5 mL/mmHg, P = 0.039.
sults are present in Table V . Cp was a stronger predictive factor of survival after adjusted by PVR, Qp, heart rate and 6-MWT. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the utility of Cp as a predictor for prognosis (Figure 3) . According to the ROC curve analysis, the optimal cut-off value of Cp for predicting mortality 1.04 mL/mmHg, with a sensitivity of 87% and specificity of 64% (AUC = 0.746, 95% CI: 0.657-0.836, P < 0.001). Kaplan-Meier survival curves in Figure  4 show that patients with Cp < 1.04 mL/mmHg had a worse prognosis (Log rank: P < 0.001).
Discussion
The main findings of the study were summarized that 1) Cp and PVR is inversely correlated in patients with APAH-CHD, and this relationship does not changed, regardless of the clinical phenotype; 2) Cp is also related with disease severity and will influence the mortality in patients with CHD and PH. To our knowledge, this is the first study aiming at verifying the implications of decreased pulmonary artery compliance in the prognosis of patients with APAH-CHD in a bigger sample study.
The normal pulmonary is a low pressure, high compliance system. Different from systemic circulation, the resistance and compliance in the pulmonary circulation exhibit an inverse hyperbolic relationship in both healthy and diseased state.
6) It had been established that pulmonary arterial compliance decreases in the condition of pulmonary hypertension due to increased pulmonary artery stiffness.
5)
Newman, et al. 10) reported that in eight vasodilator-responsive idiopathic/heritable PAH, Cp increased immediately with inhaled NO for vasodilation Cheng, ET AL Figure 2 . Mortality for three Cp tertiles. In the lowest, second and highest Cp group, the mortality was 22.4%, 15.0%, and 1.8%, respectively. test, which suggests that the compliance vessels are the same as the resistance vessels in pulmonary circulation. In comparison with patients with IPAH, the pathophysiology of PAH associated with CHD is more complicated because of the presence of a defect and shunt. However, in our study, Cp and PVR stay inversely related, which is similar as in IPAH. Most patients in this study population are Eisenmenger syndrome (64%), and patients of PAH with repaired defect and small defect account for a small part. Eisenmenger syndrome represents some of the most severe consequences of untreated CHD. An estimated 48% of patients with large unrepaired ventricular septal defects will go on to develop Eisenmenger syndrome. 11) Clinical research found that pre-tricuspid shunts tend to develop Eisenmenger syndrome later in life, compared to posttricuspid shunts.
12) This is increasing support for the concept that vascular occlusive lesions due to increased pressure rather than flow is the more important etiologic factor in developing PAH-CHD. 13) Other CHD subtypes including PAH with small and repaired defect, are considered to behave similarly with IPAH in physiology and long-term outcome. 13) In this study, the mean Qp/Qs of overall patients was 1.1 ± 0.5, and then it is reasonable to think that Cp was reduced due to distal vasculopathy rather than the shunt.
Mahapatra, et al. 14) found that Cp was a strong independent predictor of mortality in patients with IPAH, and Cp < 0.81 mL/mmHg predicted a < 40% probability of survival at 4 years. Decreased Cp is also associated with poor prognosis in patients with pulmonary hypertension due to left heart failure. 15, 16) In this study, patients with the lowest Cp had advanced WHO function class, worse exercise ability and liver function, and Cp < 1.04 mL/mmHg also had a stronger ability to predict mortality than PVR. Right ventricular afterload includes three parameters: resistance, compliance, and characteristic impedance as defined in the Windkessel model. 17) Cp and PVR adjust the steady and pulsatile afterload of RV, respectively. It has been described that pulsatile component account for about 25% of the RV afterload. 17) As a result, PVR alone predicts outcomes in PAH inconsistently in some studies. Stevens, et al. 18) established that decreased Cp is independently associated with RV dysfunction, dilatation, and hypertrophy. In our study, patients in lowest Cp group also present with higher plasma level of NT-proBNP, which represent worse RV function. It is important to mention that both right ventricular and left ventricular dysfunction is associated with increased mortality in Eisenmenger syndrome, which is different from other forms of PAH. 19) In Eisenmenger syndrome, both ventricles share the hemodynamic load. For the patients with posttricuspid shunts, both left and right ventricular bear afterload of a diseased pulmonary vasculature, and in patients with pre-tricuspid lesions, left ventricular preload is also impaired. So, left ventricular dysfunction may be another explanation of the decreased survival in patients with decreased Cp.
The development of PAH in patients with CHD is as-PULMONARY HYPERTENSION, RESISTANCE, MORTALITY sociated with increased mortality and high morbidity. 11) In the patients with severe pulmonary vascular disease in the setting of CHD, surgical correction is contraindication. There is established evidence that PAH-specific therapeutic drugs have efficacy in APAH-CHD patients. [20] [21] [22] In general, the determination of the timing of initiation of proactive or aggressive PAH-specific therapy depended on worsening of cardiac function, such as WHO function class and 6-MWD. Tan, et al. 23) considered that rather than the consequence of distal proliferative vasculopathy, decreased Cp contributed to the progressive damage of microvasculature. Loss of pulmonary artery compliance occurs early in the course of the disease process, even when PVR is normal. Pulmonary artery compliance may be an attractive target for early treatment in pulmonary hypertension. 24) Limitation: Our study had several limitations. First, the study consisted of patients referred to a single center, which may constitute a referral bias; second, because there were only twenty-three deaths, the number of events is too low for a multivariate analysis. Thus, we performed a bivariate analysis that has some statistical limitations.
However, given the better survival of Eisenmenger, 24) it may be challenging to get enough profiles of death in a single center; Third, 28% of patients in this study did not receive target therapy, which may be a limitation. However, although a beneficial effect of bosentan or sidenafil has been shown on exercise capacity and quality of life in this group of patients in previous studies, an effect on mortality remains uncertain. 25) We also examined the prognostic value of target therapy in this study, and the univariate analysis showed that target therapy was not associated with mortality. Finally, a multicenter, large cohort and long-term follow-up study may be performed to establish these findings in the future.
Conclusion
Cp and PVR stay inversely in patients with APAH-CHD; it is reasonable that not just pulmonary vascular resistance, but pulmonary arterial stiffness influences the mortality and morbidity in patients with CHD and PAH.
Disclosures

Conflict of interest:
The authors have no conflicts of interest to disclose.
